The ARANMP-LT study is a multicenter, open-label, randomized, parallel-group, non-inferiority clinical trial designed to evaluate whether avoiding graft recooling after normothermic machine perfusion (NMP) improves early outcomes following liver transplantation. Although graft recooling before implantation is common practice, experimental and preliminary clinical evidence suggests that abrupt temperature changes may contribute to ischemia-reperfusion injury. Adult recipients of deceased-donor liver grafts preserved with NMP or sequential hypothermic-normothermic machine perfusion (SHNMP) will be randomized in a 1:1 ratio to either standard graft implantation with recooling using cold preservation solution (control group) or implantation without recooling using a room-temperature 5% albumin flush immediately before reperfusion (intervention group). The primary objective is to compare the incidence of Early Allograft Dysfunction (EAD), defined according to the Olthoff criteria, between the two treatment groups. Secondary objectives include evaluation of histopathological ischemia-reperfusion injury using the Suzuki score, vascular and biliary complications, primary non-function, post-reperfusion syndrome, patient and graft survival, length of intensive care unit and hospital stay, perioperative transfusion requirements, and safety outcomes. A total of 170 participants will be enrolled across multiple Italian liver transplant centers and followed for 90 days after transplantation.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
170
After completion of normothermic machine perfusion, the liver graft is flushed with 5% albumin solution at room temperature (20-25°C) and implanted without recooling. The graft remains at near-normothermic temperature throughout the transition from ex vivo perfusion to in situ implantation, avoiding the conventional cold preservation flush before reperfusion.
After completion of normothermic machine perfusion, the liver graft undergoes the standard preservation procedure consisting of a cold preservation solution flush before implantation, resulting in graft recooling prior to reperfusion. The remainder of the transplantation procedure follows standard clinical practice.
Università Politecnica delle Marche, AUO delle Marche
Ancona, Italy
NOT_YET_RECRUITINGAzienda Ospedaliero-Universitaria Consorziale Policlinico di Bari - Ospedale Giovanni XXIII
Bari, Italy
NOT_YET_RECRUITINGASST Papa Giovanni XXIII
Bergamo, Italy
NOT_YET_RECRUITINGIRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Italy
NOT_YET_RECRUITINGOspedale Università Policlinico San Martino - IRCCS
Genova, Italy
NOT_YET_RECRUITINGUniversità di Modena e Reggio Emilia
Modena, Italy
NOT_YET_RECRUITINGAzienda Ospedale-Università di Padova
Padova, Italy
NOT_YET_RECRUITINGIRCCS ISMETT - Istituto Mediterraneo per i Trapianti e le Terapie ad Alta Specializzazione
Palermo, Italy
RECRUITINGAzienda Ospedaliero Universitaria Pisana
Pisa, Italy
NOT_YET_RECRUITINGFondazione PTV - Policlinico Tor Vergata
Roma, Italy
NOT_YET_RECRUITING...and 4 more locations
Early Allograft Dysfunction (EAD)
Incidence of Early Allograft Dysfunction (EAD), defined according to the Olthoff criteria as bilirubin ≥10 mg/dL or INR ≥1.6 on postoperative day 7, or AST/ALT \>2000 IU/L within the first 7 postoperative days.
Time frame: Within 7 days after liver transplantation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.